Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?

HÜRMÜZ, PERVİN; ÖZYİĞİT, GÖKHAN; Kilickap, Saddettin; BEDÜK ESEN, ÇAĞLAYAN; AKDOĞAN, BÜLENT; Ozen, Haluk; Akyol, HÜSNÜ

doi:10.1016/j.urolonc.2020.11.006

Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?

HÜRMÜZ P., ÖZYİĞİT G., Kilickap S., BEDÜK ESEN Ç. S., AKDOĞAN B., Ozen H., ...Daha Fazla

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, cilt.39, sa.6, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 39 Sayı: 6
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.urolonc.2020.11.006
Dergi Adı: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE
Hacettepe Üniversitesi Adresli: Evet

Özet

Purpose: Cisplatin based chemoradiation has been commonly used as a definitive treatment for muscle-invasive bladder cancer (MIBC). The aim of the current study is to evaluate oncologic results and toxicity profile of bladder-sparing treatment with external beam radiotherapy (EBRT) and gemcitabine chemotherapy (ChT) in patients with MIBC.